Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eileen Smith

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Transfusion|August 24, 2007
Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantationShirong Wang, Auayporn Nademanee, Dajun Qian, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)Brian J Ball, Shukaib Arslan, Paul Koller, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2018
Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell TransplantationMonzr M Al Malki, Nitya Nathwani, Dongyun Yang, et al.
Cancers|December 17, 2024
Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)Hoda Pourhassan, Tina Nguyen, Dongyun Yang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 7, 2005
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host diseaseFrancisco Lopez, Pablo Parker, Auayporn Nademanee, et al.
Leukemia Research|August 29, 2024
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantationAmrita Desai, Yazeed Samara, Dongyun Yang, et al.
Bone Marrow Transplantation|August 15, 2024
Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settingsSalman Otoukesh, Dongyun Yang, Sally Mokhtari, et al.
Bone Marrow Transplantation|November 18, 2025
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxisAmandeep Salhotra, Dongyun Yang, Monzr M Al Malki, et al.
Blood|July 9, 2005
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphomaAuayporn Nademanee, Stephen Forman, Arturo Molina, et al.
Leukemia & Lymphoma|August 3, 2023
<i>WT1</i>-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimensAhmed Aribi, Amandeep Salhotra, Michelle Afkhami, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Transfusion|August 24, 2007
Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantationShirong Wang, Auayporn Nademanee, Dajun Qian, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)Brian J Ball, Shukaib Arslan, Paul Koller, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2018
Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell TransplantationMonzr M Al Malki, Nitya Nathwani, Dongyun Yang, et al.
Cancers|December 17, 2024
Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)Hoda Pourhassan, Tina Nguyen, Dongyun Yang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 7, 2005
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host diseaseFrancisco Lopez, Pablo Parker, Auayporn Nademanee, et al.
Leukemia Research|August 29, 2024
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantationAmrita Desai, Yazeed Samara, Dongyun Yang, et al.
Bone Marrow Transplantation|August 15, 2024
Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settingsSalman Otoukesh, Dongyun Yang, Sally Mokhtari, et al.
Bone Marrow Transplantation|November 18, 2025
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxisAmandeep Salhotra, Dongyun Yang, Monzr M Al Malki, et al.
Blood|July 9, 2005
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphomaAuayporn Nademanee, Stephen Forman, Arturo Molina, et al.
Leukemia & Lymphoma|August 3, 2023
<i>WT1</i>-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimensAhmed Aribi, Amandeep Salhotra, Michelle Afkhami, et al.
Pageof 5